NMN and Medications: Known and Potential Interactions

NMN has not been studied in formal human drug interaction trials — the kind of pharmacokinetic studies that pharmaceutical companies conduct before seeking approval for a new drug. What exists instead is a combination of in vitro enzyme kinetic data, mechanistic reasoning from known NMN metabolic pathways, and clinical experience from practitioners who work with longevity-focused patients. This means the interaction picture is less precisely characterized than it would be for a pharmaceutical agent, with implications for how confidently any interaction can be confirmed or ruled out.

This article covers the interaction categories most relevant to the population likely to be taking NMN — middle-aged and older adults who are also more likely than average to be on prescription medications — with honest calibration of what is established, what is theoretical, and what warrants discussion with a healthcare provider. If you take any prescription medication regularly, please discuss NMN supplementation with your prescribing physician or a pharmacist before starting.

The CYP Enzyme Mechanism: Understanding the Primary Interaction Pathway

Most of NMN’s drug interaction potential operates through inhibition of cytochrome P450 (CYP) enzymes — the primary drug-metabolizing enzymes in the liver and intestinal wall. The CYP system is responsible for metabolizing approximately 70–80% of all pharmaceuticals currently in clinical use. When a compound inhibits a CYP enzyme, it reduces that enzyme’s capacity to metabolize drugs that depend on it, potentially causing those drugs to accumulate to higher plasma concentrations than intended — with corresponding increases in both therapeutic effects and adverse effects.

NMN’s primary metabolite — nicotinamide — has established inhibitory activity against CYP3A4 and CYP2C9 at concentrations achievable through supplementation. These are two of the most important drug-metabolizing CYP isoforms. CYP3A4 alone handles the metabolism of approximately 50% of all pharmaceuticals. CYP2C9 handles around 15% of pharmaceuticals, including several anticoagulants and anti-inflammatory drugs.

The clinical significance of NMN’s CYP inhibition depends on factors that have not been directly measured in human pharmacokinetic studies: the actual nicotinamide concentrations produced in the liver and intestinal wall at typical NMN supplemental doses, the potency of that inhibition relative to the drugs being co-administered, and individual variation in baseline CYP activity. In the absence of direct human drug interaction data, the appropriate posture is caution — particularly for drugs with narrow therapeutic windows where even modest changes in plasma concentration have clinical consequences.

CYP3A4-Dependent Medications: The Largest Interaction Category

CYP3A4 is involved in the metabolism of a wide range of commonly prescribed drugs. The following categories are most relevant to the NMN user demographic:

Statins

Several widely prescribed statins are significantly CYP3A4-dependent in their metabolism — simvastatin and lovastatin are the most CYP3A4-sensitive; atorvastatin is partially CYP3A4-dependent; rosuvastatin and pravastatin are not significantly CYP3A4-dependent and carry lower interaction risk. Inhibition of CYP3A4 by NMN-derived nicotinamide could raise plasma concentrations of simvastatin and lovastatin, potentially increasing the risk of statin-associated myopathy (muscle pain and weakness) and, at higher concentrations, rhabdomyolysis. This is not a theoretical concern manufactured for this article — it is why grapefruit juice (another CYP3A4 inhibitor) carries a contraindication with these statins. The magnitude of NMN’s CYP3A4 inhibition relative to grapefruit is not established.

Practical guidance: if you take simvastatin or lovastatin, discuss NMN supplementation with your prescribing physician before starting. Rosuvastatin or pravastatin users face lower risk. Monitor for any unusual muscle symptoms after starting NMN alongside any statin.

Calcium Channel Blockers

Several calcium channel blockers used for hypertension and angina — including amlodipine, felodipine, and nifedipine — are CYP3A4 substrates. Elevated plasma concentrations from CYP3A4 inhibition could enhance blood pressure-lowering effects and potentially cause hypotension. Combined with NMN’s own blood pressure-lowering effect in people with elevated baseline values, the potential for additive blood pressure reduction warrants monitoring. Discuss with your prescribing physician if you take calcium channel blockers.

Immunosuppressants

Tacrolimus and cyclosporine — immunosuppressants used in organ transplant patients and for autoimmune conditions — are highly CYP3A4-dependent with narrow therapeutic windows. Even small changes in their plasma concentrations can produce significant consequences: too high leads to immunosuppressant toxicity; too low leads to rejection or disease flare. People taking these medications should not add NMN without explicit specialist guidance.

Certain Antifungals and Antibiotics

Several antifungals (ketoconazole, itraconazole) and antibiotics (erythromycin, clarithromycin) are both CYP3A4 substrates and CYP3A4 inhibitors themselves. The interactions in this category are bidirectional: these drugs could inhibit the metabolism of NMN’s nicotinamide byproduct, and NMN’s nicotinamide could inhibit the metabolism of these drugs. For short courses of these antibiotics or antifungals, pausing NMN during the course is a reasonable precaution.

CYP2C9-Dependent Medications

Warfarin

Warfarin is the CYP2C9-dependent medication most likely to be in this readership’s prescription list. It is anticoagulant therapy with an extremely narrow therapeutic window — small changes in plasma warfarin concentration translate directly to changes in INR (international normalized ratio) and bleeding risk. CYP2C9 inhibition from NMN-derived nicotinamide could raise warfarin plasma concentrations, increasing anticoagulant effect and bleeding risk.

Additionally, vitamin K2 — which many people take alongside NMN in a longevity stack — directly affects warfarin’s mechanism of action. Vitamin K is the substrate that warfarin antagonizes; adding K2 supplementation can significantly reduce warfarin’s anticoagulant efficacy. Anyone taking warfarin should not add either NMN or vitamin K2 without close coordination with their prescribing physician and INR monitoring.

NSAIDs and COX-2 Inhibitors

Several non-steroidal anti-inflammatory drugs including ibuprofen, naproxen, and celecoxib are CYP2C9 substrates. For people using these occasionally, the interaction risk is modest. For people taking them chronically for pain or inflammation, discussing NMN with their physician is appropriate.

Certain Antidiabetic Medications

Glipizide and glibenclamide — sulfonylurea diabetes medications — are CYP2C9-dependent. Combined with NMN’s insulin-sensitizing effect (demonstrated in the Yoshino 2021 trial), there is both a pharmacokinetic interaction risk (elevated sulfonylurea from CYP2C9 inhibition) and a pharmacodynamic interaction risk (additive glucose lowering) that could produce hypoglycemia. This combination warrants physician awareness and blood glucose monitoring.

Additive Pharmacodynamic Interactions

Beyond CYP enzyme interactions, several additive pharmacodynamic effects — where NMN’s biological activity combines with a medication’s therapeutic action — warrant attention.

Blood Glucose-Lowering Medications

Metformin, insulin, GLP-1 receptor agonists, SGLT2 inhibitors, and sulfonylureas all lower blood glucose through various mechanisms. NMN has demonstrated insulin-sensitizing effects in the Yoshino trial — producing improved skeletal muscle glucose uptake in women with prediabetes. Adding NMN alongside established glucose-lowering medications creates the potential for additive hypoglycemia. This risk is probably small at typical NMN doses in most patients, but monitoring blood glucose after starting NMN is prudent for anyone on these medications. Consult your prescribing physician before adding NMN to a diabetes management regimen.

Antihypertensive Medications

NMN has shown blood pressure-lowering effects in people with elevated baseline values (Martens 2018 NR trial; Liao 2021 NMN trial). For people on antihypertensive medications, an additive blood pressure-lowering effect could produce symptomatic hypotension — dizziness, lightheadedness, or falls, the latter being particularly relevant for older adults. Monitoring blood pressure after starting NMN alongside antihypertensives is practical and appropriate.

Anticoagulants and Antiplatelet Agents

Beyond warfarin, the newer direct oral anticoagulants (DOACs) — apixaban, rivaroxaban, dabigatran — are used widely for atrial fibrillation and thromboembolism prevention. These drugs are CYP3A4 and P-glycoprotein substrates (apixaban and rivaroxaban in particular). NMN’s CYP3A4 inhibition could raise DOAC concentrations, potentially increasing bleeding risk. Antiplatelet agents like clopidogrel involve CYP2C19 more than CYP3A4 or CYP2C9, so the NMN interaction risk is lower but not zero. Anyone on anticoagulation therapy of any type should discuss NMN supplementation with their prescribing physician or anticoagulation clinic before starting.

The Full Longevity Stack: Compounded Interaction Risk

A consideration that is specific to the longevity supplement context rather than NMN alone: many longevity protocols combine NMN with resveratrol, quercetin, and berberine — all of which have their own CYP-inhibitory activity. The combined CYP inhibition from a full longevity stack can be substantially greater than from NMN alone.

Resveratrol inhibits CYP3A4, CYP2C9, and CYP1A2. Quercetin inhibits CYP3A4, CYP2C9, and CYP2D6. Berberine inhibits CYP3A4 and CYP2D6. When these are combined with NMN — all of whose metabolites inhibit CYP3A4 and CYP2C9 — the aggregate inhibitory effect on drug metabolism could be clinically significant for patients on multiple CYP-dependent medications, even if each individual compound’s contribution would be subthreshold.

For people on several prescription medications, a pharmacist with access to their full medication list is the most appropriate person to assess whether the combined CYP inhibition from their supplement stack poses a meaningful drug interaction risk. This is a practical recommendation with real clinical value, not a reflexive safety disclaimer.

Medications That Are Relatively Lower Risk Alongside NMN

Not every medication carries meaningful interaction risk with NMN. Drugs metabolized primarily through non-CYP pathways — glucuronidation, sulfation, renal clearance — are less likely to be significantly affected. This includes many beta-blockers (metoprolol is partially CYP2D6-dependent but not CYP3A4 or CYP2C9), most diuretics, thyroid hormones (though NMN’s potential effects on thyroid medication absorption through gut microbiome changes is unstudied), and most ACE inhibitors and ARBs.

This is not a comprehensive clearance — a pharmacist review of your specific medications is more reliable than any generalization — but it illustrates that NMN does not pose uniform interaction risk across all drug classes.

Frequently Asked Questions

How do I find out if my specific medication interacts with NMN?

The most practical approach is a combination of checking your medication’s primary metabolic pathway (available in the prescribing information or through clinical pharmacology databases) and discussing with your pharmacist. Pharmacists have access to interaction-checking tools and your complete medication list, making them better equipped than most physicians to assess polypharmacy interaction risk. Asking specifically whether your medications are CYP3A4 or CYP2C9 substrates, and whether moderate CYP inhibition would be clinically significant for them, is a focused and answerable question.

Should I stop taking NMN before surgery?

Many surgeons and anesthesiologists recommend stopping all supplements one to two weeks before elective surgery. NMN’s potential effects on drug metabolism and its blood pressure-lowering activity could theoretically affect anesthetic management. Disclosing NMN (and all other supplements) to your surgical and anesthesia team before any procedure is important — most medical intake forms ask about supplements, and “I take some longevity supplements” is not a substitute for specifically naming NMN, resveratrol, and others. Follow your surgical team’s guidance on whether and when to discontinue supplements pre-operatively.

Can I take NMN with metformin?

Metformin is primarily eliminated renally rather than metabolized by CYP enzymes, so the CYP interaction concern is less relevant here than for many other drugs. The more relevant consideration is additive glucose-lowering — both metformin and NMN improve insulin sensitivity, and their combined effect on blood glucose warrants monitoring. Metformin and NMN target complementary pathways (AMPK activation vs. NAD+ elevation), making them mechanistically rational to combine in principle. If you take metformin and are considering adding NMN, discuss this with your prescribing physician and monitor fasting glucose after starting.

Does the interaction risk change at lower NMN doses?

Yes, in principle — CYP inhibition from nicotinamide metabolites is concentration-dependent, and lower NMN doses produce lower nicotinamide concentrations. At 250 mg/day NMN, the nicotinamide burden and the CYP inhibition are both smaller than at 1,000 mg/day. For people with drug interaction concerns, starting at a lower NMN dose while monitoring for changes in medication effects is a pragmatic harm-reduction approach while the interaction is being assessed. This does not eliminate the interaction risk but reduces it proportionally with dose.